The bio-pharmaceutical industry is the material basis for the health of the people of the country and the realization of a comprehensive well-off society. In recent years, with the support of national policies for the bio-pharmaceutical industry, the Chinese bio-pharmaceutical market is welcoming rapid development. It is estimated that by 2020, Chinese organisms The pharmaceutical market will be twice as large as Japan.
The data shows that the 2016 Chinese hospital biomedical market is as large as $78 billion, which does not include the share of primary care and retail channels. In 2017, the market size of the biomedical industry was 341.171 billion yuan, a slower growth than the year-on-year growth. In 2014, China surpassed Japan to become the world's second largest biomedical market. It is expected that by 2020, China's biomedical market will be twice as large as Japan.
With the development of China's economy, changes in living environment, changes in people's health concepts, and the acceleration of the aging process of the population, the biomedical industry, which is closely related to the quality of human life, has maintained a trend of continuous growth in recent years. The world's second largest economy has also played a positive role in the field of biomedicine.
In recent years, the state has issued a series of policies and plans, and the government orientation will undoubtedly become a major positive factor for the rapid development of biopharmaceuticals in China. For example, in "Made in China 2025", biomedicine is listed as one of the ten key areas. It mentions the development of new biotech drug products for major diseases, focusing on new mechanisms and new target antibody drugs, antibody-conjugated drugs, new structural and peptide drugs, and new vaccines. The 13th Five-Year Plan also takes breakthroughs in new medical technologies as one of the key development directions. The “Healthy China 2030 Plan†also focuses on promoting the development of the pharmaceutical industry. The state expects that the medical and health industry will reach US$2.5 trillion by 2030.
In order to accelerate the transformation of scientific and technological achievements, it is of great significance to accelerate the cultivation of strategic emerging industries of biomedicine. It is reported that on August 28, Huaxia Happiness Foundation Co., Ltd. and China Biotechnology Development Center established a strategic partnership to sign a framework agreement in Beijing. The two sides will join hands in the Chinese biomedical industry
New kinetic energy, new technologies, new industries and other aspects will cooperate in research, organize industry research and exchange activities, and jointly promote the development of biomedical industry.
Strengthening medical technology innovation and improving the level of industrial development are important support for the implementation of the "healthy China" strategy. It is an important duty of China Biotechnology Development Center to carry out strategic research and policy analysis in the field of biotechnology in China and promote scientific and technological innovation, transformation of results and industrialization in the field of biotechnology.
It is reported that based on the development status of the bio-pharmaceutical industry, Suzhou City has formulated the “Guiding Opinions on Accelerating the Development of the Bio-pharmaceutical Industry in Suzhou†and the “Work Plan for the Construction of the “1+N†Development Model of the Biomedical Industry in Suzhouâ€. “1†refers to the construction of a core area, which is the Suzhou Industrial Park. “N†is the construction of nine growth poles in addition to the Suzhou Industrial Park in the city. In the future, the scale of development will reach 200 billion by 2020.
At present, the proportion of biopharmaceuticals in China is relatively low, accounting for about 10% of the entire pharmaceutical market, lower than the global average (20%). Among them, the 2016 Chinese biologics CDMO market reached US$300 million. However, the industry said that driven by national policies and more and more biopharmaceuticals, it is expected to reach 1.5 billion U.S. dollars by 2020. The growth rate is very fast and the market potential is very large.
Biomedicine is known as the "crown jewel" of the new round of technological revolution. On the road of “winning the treasure†in the country, hundreds of billions of emerging industries are emerging, driving the leap-forward development of the competitiveness of the big health industry. The industry said that the bio-pharmaceutical industry is booming now, and in the future, China will realize the overtaking of corners for the birth of more biopharmaceutical unicorns.
Cosmetics are a mixture of various raw materials through reasonable allocation and processing. There are many kinds of Cosmetic Raw Material with different properties. According to the properties and uses of Raw Materials, cosmetics can be broadly divided into Whitening Raw Materials, anti-aging Raw Materials, Moisturizing Raw Materials, Powder For Eye Cream. Cosmetics are natural, synthetic or extracted substances with different functions as raw materials, and processed by heating, stirring and emulsifying production procedures.
Moisturizing Raw Materials is an essential raw material for cream cosmetics, its role is to prevent the cream dry crack, keep skin moisture.
Moisturizing Raw Materials,Aloe Vera Extract,Centella Asiatica Extract,Liposomal Rice Bran Extract
Shaanxi Changsheng Industrial Co., Ltd. , https://www.sxcsmalehealth.com